Relationship between efficacy outcomes and weight gain during treatment of advanced, non-squamous, non-small-cell lung cancer patients

摘要: ABSTRACT Background Unintentional weight loss occurs among advanced non-small-cell lung cancer (NSCLC) patients and is associated with worse survival. Small studies have suggested that gain during treatment superior Patients methods A retrospective analysis analyzed data from three international phase III comprising 2301 advanced, non-squamous NSCLC who received a platinum-based, first-line doublet, or without bevacizumab maintenance therapy. Body was recorded before after by each study's schedule. The relationship between overall survival (OS) progression-free (PFS) assessed using log-rank test adjusted Cox modeling. Logistic regression the association baseline covariates post-baseline gain. Results Four hundred twenty-one (18.3%) had >5% baseline. More than half of cohort exhibited initial 3 weeks. median OS 16.7 months versus 10.7 for ≤5% subgroup (n = 1880) (P 5% longer [hazard ratio (HR) 0.54, 95% confidence interval (CI) 0.47–0.62; P ≤5%) age, BMI. Conclusions Weight may be an early indicator clinical benefit. If confirmed in prospective studies, monitoring change provide important information regarding outcomes ideas new therapeutic strategies.